[HTML][HTML] Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized …
G de Bruyn, J Wang, A Purvis, MS Ruiz… - …, 2023 - thelancet.com
Background In a parallel-group, international, phase 3 study (ClinicalTrials. gov
NCT04762680), we evaluated prototype (D614) and Beta (B. 1.351) variant recombinant …
NCT04762680), we evaluated prototype (D614) and Beta (B. 1.351) variant recombinant …
[引用][C] Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized …
G de Bruyn, J Wang, A Purvis, MS Ruiz… - …, 2023 - produccioncientifica.ucm.es
Background: In a parallel-group, international, phase 3 study (ClinicalTrials. gov
NCT04762680), we evaluated prototype (D614) and Beta (B. 1.351) variant recombinant …
NCT04762680), we evaluated prototype (D614) and Beta (B. 1.351) variant recombinant …
[HTML][HTML] Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized …
G de Bruyn, J Wang, A Purvis, MS Ruiz, H Adhikarla… - eClinicalMedicine, 2023 - Elsevier
Background In a parallel-group, international, phase 3 study (ClinicalTrials. gov
NCT04762680), we evaluated prototype (D614) and Beta (B. 1.351) variant recombinant …
NCT04762680), we evaluated prototype (D614) and Beta (B. 1.351) variant recombinant …
Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines …
G de Bruyn, J Wang, A Purvis, MS Ruiz, H Adhikarla… - …, 2023 - hal.science
Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with
AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3 …
AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3 …
[引用][C] Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized …
G de Bruyn, J Wang, A Purvis, MS Ruiz… - …, 2023 - espace.library.uq.edu.au
[HTML][HTML] Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized …
G de Bruyn, J Wang, A Purvis, MS Ruiz, H Adhikarla… - 2022 - europepmc.org
Background Booster vaccines providing protection against emergent SARS-CoV-2 variants
are needed. In an international phase 3 study, we evaluated booster vaccines containing …
are needed. In an international phase 3 study, we evaluated booster vaccines containing …
Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines
G de Bruyn, J Wang, A Purvis, MS Ruiz, H Adhikarla… - medRxiv, 2022 - medrxiv.org
Background Booster vaccines providing protection against emergent SARS-CoV-2 variants
are needed. In an international phase 3 study, we evaluated booster vaccines containing …
are needed. In an international phase 3 study, we evaluated booster vaccines containing …
Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines …
G de Bruyn, J Wang, A Purvis, MS Ruiz… - …, 2023 - u-paris.hal.science
Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with
AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3 …
AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3 …
[HTML][HTML] Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized …
G de Bruyn, J Wang, A Purvis, MS Ruiz… - …, 2023 - ncbi.nlm.nih.gov
Methods Adults, previously primed with mRNA (BNT162b2, mRNA-1273), adenovirus-
vectored (Ad26. CoV2. S, ChAdOx1nCoV-19) or protein (CoV2 preS dTM-AS03 [monovalent …
vectored (Ad26. CoV2. S, ChAdOx1nCoV-19) or protein (CoV2 preS dTM-AS03 [monovalent …
Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines …
G de Bruyn, J Wang, A Purvis, MS Ruiz… - …, 2023 - hsrc.himmelfarb.gwu.edu
BACKGROUND: In a parallel-group, international, phase 3 study (ClinicalTrials.
govNCT04762680), we evaluated prototype (D614) and Beta (B. 1.351) variant recombinant …
govNCT04762680), we evaluated prototype (D614) and Beta (B. 1.351) variant recombinant …